Rachel Lanning1, Tristram A Lett1,2, Arun K Tiwari1,3, Eva J Brandl1,2, Vincenzo de Luca1,3,4, Aristotle N Voineskos1,3,4, Steven G Potkin5, Jeffrey A Lieberman6, Herbert Y Meltzer7, Daniel J Müller1,3,4, Gary Remington1,3, James L Kennedy1,3,4, Clement C Zai1,3,8. 1. Neurogenetics Section, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada. 2. Department of Psychiatry, Charité University Medicine Berlin, Berlin, Germany. 3. Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada. 4. Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada. 5. Department of Psychiatry and Human Behavior, University of California, Irvine, California, USA. 6. Department of Psychiatry, Mental Health and Neuroscience Center, the University of North Carolina at Chapel Hill School of Medicine, North Carolina, USA. 7. Psychiatry and Behavioral Sciences, Pharmacology and Physiology, Chemistry of Life Processes Institute, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. 8. Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
Abstract
OBJECTIVE: Tardive dyskinesia (TD) is a motor side effect that may develop after long-term antipsychotic treatment. Schizophrenia has recently been associated with the Neurexin-1 (NRXN1) gene that codes for a cell adhesion molecule in synaptic communication. METHODS: This study examined five NRXN1 single-nucleotide polymorphisms (SNPs) for possible association with the occurrence and severity of TD in 178 schizophrenia patients of European ancestry. RESULTS: We did not find these SNPs to be significantly associated with TD. CONCLUSIONS: More research is needed with additional SNPs and in bigger samples before we can completely rule out the role of NRXN1 in TD.
OBJECTIVE:Tardive dyskinesia (TD) is a motor side effect that may develop after long-term antipsychotic treatment. Schizophrenia has recently been associated with the Neurexin-1 (NRXN1) gene that codes for a cell adhesion molecule in synaptic communication. METHODS: This study examined five NRXN1 single-nucleotide polymorphisms (SNPs) for possible association with the occurrence and severity of TD in 178 schizophreniapatients of European ancestry. RESULTS: We did not find these SNPs to be significantly associated with TD. CONCLUSIONS: More research is needed with additional SNPs and in bigger samples before we can completely rule out the role of NRXN1 in TD.
Authors: Clement C Zai; Frankie H Lee; Arun K Tiwari; Justin Y Lu; Vincenzo de Luca; Miriam S Maes; Deanna Herbert; Anashe Shahmirian; Sheraz Y Cheema; Gwyneth C Zai; Anupama Atukuri; Michael Sherman; Sajid A Shaikh; Maria Tampakeras; Natalie Freeman; Nicole King; Daniel J Müller; Lior Greenbaum; Bernard Lerer; Aristotle N Voineskos; Steven G Potkin; Jeffrey A Lieberman; Herbert Y Meltzer; Gary Remington; James L Kennedy Journal: Front Pharmacol Date: 2018-09-18 Impact factor: 5.810